| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
|
|---|---|
| ln Vitro |
Endogenous metabolites are those that the Kyoto Encyclopedia of Genes and Genomes has identified as products or substrates of the approximately 1900 metabolic enzymes that are encoded in human genome. Numerous of these metabolites have been shown to have harmful effects, as evidenced by the body of literature [1].
|
| References |
|
| Additional Infomation |
Phytanic acid is a branched-chain saturated fatty acid composed of hexadecanoic acid with methyl substituents at positions 3, 7, 11, and 15. It is a branched-chain saturated fatty acid, a long-chain fatty acid, and a methyl-branched fatty acid. Its function is related to hexadecanoic acid. It is the conjugate acid of phytate esters. It is derived from the hydride of phytane. Phytanic acid has been reported in Homo sapiens, sea hares (Aplysina lacunosa), and tubular sea hares (Aplysina fistularis), with relevant data available. Phytanic acid is a 20-carbon branched-chain fatty acid found in animal (mainly herbivorous or omnivorous) tissues, possibly derived from chlorophyll in ingested plant material. Phytanic acid is derived from the corresponding alcohol compound phytol, which is ultimately oxidized to isophytanic acid. In phytanic acid storage diseases (Rifsum disease), this lipid can account for up to 30% of total fatty acids in plasma. Elevated phytanic acid levels in Rifsum disease (a neurological disorder) are due to a deficiency of phytanic acid α-hydroxylase. Phytanic acid is a 20-carbon branched-chain fatty acid. In phytanic acid storage disease (Revsoum disease), this lipid can account for up to 30% of the total fatty acids in the plasma. This is due to a deficiency of phytanic acid α-hydroxylase.
|
| Molecular Formula |
C20H40O2
|
|---|---|
| Exact Mass |
312.302
|
| CAS # |
14721-66-5
|
| Related CAS # |
Phytanic acid-d3;1383920-40-8
|
| PubChem CID |
26840
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
422.3±13.0 °C at 760 mmHg
|
| Melting Point |
-65°C
|
| Flash Point |
179.7±11.2 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.454
|
| LogP |
8.54
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
22
|
| Complexity |
273
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)O
|
| InChi Key |
RLCKHJSFHOZMDR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H40O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h16-19H,6-15H2,1-5H3,(H,21,22)
|
| Chemical Name |
3,7,11,15-tetramethylhexadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
